A new publication referencing retatrutide appeared on September 10, 2026. The article, titled "Cardiovascular Effects of Incretin Receptor Agonists: Beyond Glycemic Control," was published in the Canadian Journal of Physiology and Pharmacology.
The publication is indexed under PubMed ID 42721492. It is listed as covering incretin receptor agonists as a class, with retatrutide named among the compounds discussed.
This entry reflects the publication record only. No specific findings, data points, or conclusions from the article are included in this brief. Readers interested in the full content of the review should consult the journal directly through the listed source.
Retatrutide holds approved regulatory status as referenced in this record. For additional background on the compound, readers can consult the compound overview.